|
Events
June 1-5, 2012 Event: ASCO's 2012 Annual Meeting Where: Chicago, IL What: Neogenix Oncology will present "A phase 1 safety study of NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers" at ASCO's annual meeting being held at McCormick Place in Chicago. Click for event details view poster January 19-21, 2012 Event: ASCO's 2012 Gastrointestinal Cancers Symposium Where: San Francisco, CA What: Dr. Michael Morse of Duke University Medical Center will present a poster pertaining to the Neogenix clinical trial at Duke, entitled: "A Phase I/IIA Safety Study of NPC-1C: A Novel Therapeutic Antibody to Treat Pancreas and Colorectal Cancers" Click for event details view poster November 15, 2011 Event: 2011 AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference Where: San Francisco, CA What: Neogenix Oncology CEO Dr. Philip M. Arlen will present abstract entitled "Tissue Expression Profile of Novel Tumor Biomarkers Identified by Monoclonal Antibodies" view abstract view poster Click for event details November 3, 2011 Event: Society for Immunotherapy of Cancer Workshop Where: Bethesda North Marriott Hotel & Conference Center, Bethesda, MD What: Neogenix Oncology CEO Dr. Philip M. Arlen will be a panel speaker at "Workshop on Immunotherapy Combinations" Click for event details October 15-19, 2011 Event: Congress of the International Society of Oncology and Biomarkers Where: Florence, Italy What: Neogenix Oncology will present a paper on October 19 entitled, "The Use of Specific Antibodies Capable of Controlling Pancreatic Ca." The paper will cover the mechanisms of the Neogenix antibody now in clinical trials. Click for event details September 12-14, 2011 Event: IBC's 8th Annual Early Development Forum on Preclinical Scale Bioprocessing Where: Doubletree Mission Valley, CA What: Neogenix Senior Vice President for Research & Development, Dr. Andrew Bristol, will speak about comparability testing of GMP drug lots in early clinical development Click for event details September 7-9, 2011 Event: Cambridge Healthtech Institute's Annual ADAPT Congress Where: Loew's Philadelphia Hotel, Philadelphia, PA What: Neogenix CEO Philip M. Arlen, MD to speak about the company's novel antibodies Click for event details September 7-9, 2011 Event: Cambridge Healthtech Institute's Annual ADAPT Congress Where: Loew's Philadelphia Hotel, Philadelphia, PA What: Neogenix CEO Philip M. Arlen, MD to speak about the company's novel antibodies Click for event details August 18, 2011 Event: Shareholders Conference Call When: 11:00 a.m. Eastern Time Click for details about submitting questions June 17, 2011 Meeting: Annual Shareholders Meeting for Neogenix Oncology, Inc. Where: Inn at Great Neck 30 Cutter Mill Rd, Great Neck, NY 11021 When: 11:00 a.m. local time view powerpoint June 3-7, 2011 Meeting: ASCO Annual Meeting 2011 Where: McCormick Place, Chicago, IL Meeting website: : click here Researchers from Johns Hopkins University Hospital will give a poster presentation on the phase 1 study of the company's lead product candidate, NPC-1C (also known as NEO-101 or ensituximab). Abstract Title: A phase 1 study of NPC-1C, a novel therapeutic antibody to treat pancreas and colorectal cancers view abstract view poster April 2-6, 2011 Meeting: AACR Annual Meeting 2011 Where: Orange County Convention Center, Orlando, FL Meeting website: click here Neogenix Oncology will be presenting previously unreleased pre-clinical data on its lead product candidate, NEO-101, and on its second therapeutic candidate, NEO-201. Abstract Title: Pre-Clinical Studies of a Novel Antibody to Treat Pancreatic and Colorectal Cancers view abstract view poster Abstract Title: Characterization of a New Antibody That Reacts with a Tumor-Specific Variant of CEACAM-5 and CEACAM-6 view abstract view poster January 20-22, 2011 Meeting: ASCO 2011 Gastrointestinal Cancers Symposium Where: Moscone Center, San Francisco, CA Meeting website: click here Clinical trial data on Neogenix Oncology® therapeutic candidate will be presented by Johns Hopkins University Hospital and Neogenix Oncology. Abstract Title (Johns Hopkins presentation): NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers. view abstract view poster Abstract Title (Neogenix Oncology® presentation): Development of a new stool biomarker ELISA for the early detection of colorectal cancer. view abstract view poster October 27-30, 2010 Meeting: AACR Special Conference on Colorectal Cancer: Biology to Therapy Where: Philadelphia, PA Meeting website: click here Neogenix will be presenting the following abstract: “A Novel Antibody That Can Detect a Serum Biomarker: Utility for Detection and Prognosis in Colorectal and Pancreatic Cancer” view abstract view poster October 23-26, 2010 Meeting: 8th Annual Congress of International Drug Discovery Science and Technology (IDDST) Where: Bejing, China Meeting website: www.iddst.com/iddst2010 XuePing Wang, MD, Director Molecular Genetics Research will be presenting view abstract view poster October 18-20, 2010 Meeting: ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer Where: Hollywood, FL Meeting website: www.molecularcameeting.org Neogenix will be presenting the following abstract: “Diagnostic/prognostic utility of a new serum biomarker ELISA for colorectal and pancreatic cancers” view abstract view poster October 11, 2010 Meeting: BioPartnering Europe Where: London, UK Meeting website: www.techvision.com/bpe Peter Gordon, Neogenix CFO, to present company overview and highlights of progress |
ADDITIONAL INFORMATION
For more information, please contact: RoseMarie Terenzio RMT PR Management 212-414-1909 or 917-913-7226 (cell) rterenzio@rmtpr.com |
 |